Pascal Deschatelets - 12 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: APLS
Reported as of: 12 Jan 2023
Net transaction value: +$1,624,298
SEC form: 4
Accepted by SEC: 17 Jan 2023, 18:33:38 UTC
Prior SEC filing: 10 Jan 2023
Next SEC filing: 24 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets

Key filing fact

Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 17 Jan 2023.

Key facts

This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 17 Jan 2023, 18:33.

Change

Previous filing in this sequence was filed on 10 Jan 2023.
Current net transaction value: +$1,624,298.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Common Stock

Award

Transaction value: $0
Shares: +19,634
Change %: +2%
Price: $0.000000
Shares after: 1,003,414
Date: 12 Jan 2023
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $1,624,298
Shares: +30,845
Change %
Price: $52.66
Shares after: 30,845
Date: 12 Jan 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,845
Exercise price: $52.66
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This represents a Restricted Stock Award granted 01/12/23 that vest annually from grant date over a four year period subject to continued service.

Footnote F2

This represents a stock option award granted 01/12/2023 that vest over a four year period. 25% vest one year from grant date and the remaining 75% vest monthly thereafter subject to continued service.